

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Johannes REINMUELLER, et al. : Group Art Unit.: 2694
Serial No.: 10/586,345 : Examiner: Scarlett Y. Goon
Filed: July 13, 2006 :
Title: COMPOSITION FOR TREATING INFLAMMATORY DISEASES

REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

In response to the Office Action mailed on October 24, 2008, and concurrently filed RCE, please consider the following.

Claim Rejections Under 35 USC § 103

The claims are rejected as allegedly unpatentable over Falk in view of Sakurai and Fischer.

Falk is concerned with the treatment of diseases of the skin and exposed tissue, which treatment comprises administration of a composition comprising an inhibitor of prostaglandine synthesis in combination with hyaluronic acid and/or salts thereof. The composition is topically administered and can be employed in the treatment of, for example, genital warts, human papilloma virus and psoriasis.

Sakurai discloses hyaluronic acid in crosslinked form having a crosslinking degree of between 0.75% to 4%, as well as its use for a cosmetic treatment of the skin. According to the citation, hyaluronic acid in crosslinked form has the advantage that is resistant to enzymatic and oxidative/reductive degradation while maintaining different properties of uncrosslinked hyaluronic acid.

Fischer discloses a non-invasive and non-systemic method for administering a local anesthetic, which method comprises applying a combination of a local anesthetic and a penetration agent selected from the group consisting of an aloe composition, a triglyceride